Case No. 10466/73 TRANSMITTAL LETTER Examiner Group Art Unit Filing Date 1645 09/902,853 July 10, 2001 To be assigned Inventor(s) Ashkenazi et al. Title of Invention SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC ACIDS ENCODING THE SAME TO THE COMMISSIONER FOR PATENTS Transmitted herewith is an Information Disclosure Statement; Form PTO-1449; 2 cited references and return postcard Small entity status of this application under 37 CFR § 1.27 has been established by verified statement previously submitted. A verified statement to establish small entity status under 37 CFR §§ 1.9 and 1.27 is enclosed. \_\_\_month extension of time. No additional fee is required. The fee has been calculated as shown below: Other Than Small Entity Small Entity Highest No. or Claims Add'l Remaining Previously Present Add'i Rate Rate Fee Paid For Extra Fee After Amendment x \$18= Total Minus x \$9= x \$84= x 42= Indep. Minus + \$280= +\$140= First Presentation of Multiple Dep. Claim Total Total add'I fee add'I fee Please charge Deposit Account No. 23-1925 (BRINKS HOFER GILSON & LIONE) in the amount of \$\_\_\_\_\_. A duplicate copy of this sheet is enclosed. A check in the amount of \$ \_\_\_\_ to cover the filing fee is enclosed. The Commissioner is hereby authorized to charge payment of any additional filing fees required under 37 CFR § 1.16 and any patent application processing fees under 37 CFR § 1.17 associated with this communication or credit any overpayment to Deposit Account No. 23-1925. A duplicate copy of this sheet is enclosed. M I hereby petition under 37 CFR § 1.136(a) for any extension of time required to ensure that this paper is timely filed. Please charge any associated fees which have not otherwise been paid to Deposit Account No. 23-1925. A duplicate copy of this sheet is enclosed. Respectfully submitted,

> Paul E. Rauch, Ph.D. Registration No. 38,591 Attorney for Applicant

**BRINKS HOFER GILSON & LIONE** P.O. BOX 10395 CHICAGO, ILLINOIS 60610 (312) 321-4200

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail, with sufficient postage, in an envelope addressed to: Commissioner for Patent Washington, D.C. 20231, on

rev. Dec.-00 Document2